Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis

NEXT STORY
Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences
PREV STORY
Global PCR Markets Outlook 2021-2025: qPCR, dPCR, Singleplex & Multiplex Markets – Point of Care Testing and Molecular Diagnostics are Merging with Spectacular Success
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC Patients Post Checkpoint Inhibitor Failure Following IDMC Recommendation

author_avatar
NASDAQ Market News

Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**

SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS)[1] EXCEED ...

author_avatar
NASDAQ Market News

Evaxion Biotech Announces Filing of Registration Statement in the U.S. for Proposed Initial Public Offering of Securities

author_avatar
NASDAQ Market News